OCT 26, 2016
In this interview from AAO 2016, Dr. Debra A. Goldstein discusses the recent FDA approval of adalimumab for non-infectious uveitis. Before these anti-tumor necrosis factor (TNF) agents were introduced, physicians relied on steroid-sparing agents that allowed for tapering of corticosteroids, but were not as effective. TNF inhibitors may achieve complete quiescence of uveitis, but their use up until recently was off-label. With FDA approval, patients should expect to receive more consistent insurance coverage. According to Dr. Goldstein, some off-label practices will continue, as the biologics she prefers - both adalimumab and infliximab - must be administered at higher doses and more frequently for uveitis than for joint diseases.